Personalized medicine in rheumatoid arthritis: Is the glass half full or half empty?

Journal of Internal Medicine

Volumn 277, Issue 2, 2015, Pages 178-187

  Huizinga, T W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Autoantibodies; Autoimmune diseases; Rheumatoid; Treat to target; Treatment strategies

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; B7 ANTIGEN; CD86 ANTIGEN; CITRULLINE; INFLIXIMAB; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

AGE; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENDER; GENETIC RISK; HEREDITY; HUMAN; PATIENT CARE; PATIENT MONITORING; PERSONALIZED MEDICINE; PHYSICAL DISEASE BY BODY FUNCTION; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ALGORITHM; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; EVIDENCE BASED MEDICINE; IMMUNOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD80; ANTIGENS, CD86; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; INTERLEUKIN-6; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921515732     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12319     Document Type: Article

References (68)

1. Bennett GA, Cobb S, Jacox R, Jessar RA, Ropes MW. Proposed diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1956; 7: 121-4.
2. Drossaers-Bakker KW, Kroon HM, Zwinderman AH, Breedveld FC, Hazes JM. Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. Rheumatology (Oxford) 2000; 39: 998-1003.
3. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37: 1492-8.
4. Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 291-8.
5. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
6. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 177-81.
7. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 9430: 263-9.
8. van Nies JA, de Jong Z, van der Helm-van Mil AH, Knevel R, Le Cessie S, Huizinga TW. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 2010; 49: 2210-6.
9. Puolakka K, Kautiainen H, Pohjolainen T, Virta L. No increased mortality in incident cases of rheumatoid arthritis during the new millennium. Ann Rheum Dis 2010; 69: 2057-8.
10. Wevers-de Boer KV, Heimans L, Huizinga TW, Allaart CF. Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis 2013; 72: 1436-44.
11. Machold KP, Landewé R, Smolen JS et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010; 69: 495-502.
12. van Aken J, Heimans L, Gillet-van Dongen H et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 2014; 73: 396-400.
13. van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The Leiden early arthritis clinic. Clin Exp Rheumatol 2003; 21(5 Suppl 31): S100-5.
14. Hulsemann JL, Zeidler H. Undifferentiated arthritis in an early synovitis out-patient clinic. Clin Exp Rheumatol 1995; 13: 37-43.
15. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
16. van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis - comparison of the 1987 ACR and 2010 ACR/EULAR criteria. Arthritis Rheum 2011; 63: 37-42.
17. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
18. Dougados M, Jousse-Joulin S, Mistretta F et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 828-33.
19. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625-31.
20. van der Helm-van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1694-6.
21. Gerlag DM, Raza K, van Baarsen LG et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71: 638-41.
22. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 433-40.
23. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
24. van der Helm-van Mil AH, Detert J, le Cessie S et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58: 2241-7.
25. Kuriya B, Cheng CK, Chen HM, Bykerk VP. Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis. Ann Rheum Dis 2009; 68: 1482-5.
26. Tamai M, Kawakami A, Uetani M et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum 2009; 61: 772-8.
27. Bradna P, Soukop T, Bastecj D, Hrncir J. Prediction rule in early and very early arthritis patients. Ann Rheum Dis 2009; 68(Suppl 3): 547.
28. Luchikhina E, Karateev DE, Nasonov EL. The use of prediction rule to predict the development of rheumatoid arthritis in russian patients with early undifferentiated arthritis. Ann Rheum Dis 2008; 58: 2241-7.
29. Mjaavatten MD, van der Helm-van Mil AH, Huizinga TW et al. Validation of a proposed prediction rule for rheumatoid arthritis in a cohort of 188 patients with undifferentiated arthritis. Ann Rheum Dis 2012; 67(Suppl II): 477.
30. Wevers-de BK, Visser K, Heimans L et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012; 71: 1472-7.
31. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013; 72: 3-6.
32. Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 507-13.
33. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005; 44: 1026-31.
34. Weinblatt ME, Fleischmann R, Huizinga TW et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012; 51: 2204-14.
35. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 2013; 43: 9-17.
36. Wang J, Platt A, Upmanyu R et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013; 3: e003199.
37. Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68: 1708-14.
38. Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228-34.
39. Isaacs JD, Cohen SB, Emery P et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-36.
40. Kremer JM, Tony H, Tak PP et al. Efficacy of rituximab in active ra patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006; 65: 326.
41. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
42. Shi J, Knevel R, Suwannalai P et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108: 17372-7.
43. van der Linden MP, van der Woude D, Ioan-Facsinay A et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
44. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R949-58.
45. Huizinga TW, Amos CI, van der Helm-van Mil AH et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52: 3433-8.
46. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008; 10: 205.
47. De Rooy DP, Willemze A, Mertens B, Huizinga TW, van der Helm-van Mil AH. Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther 2011; 13: R180.
48. Snir O, Widhe M, Hermansson M et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 44-52.
49. Amara K, Steen J, Murray F et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210: 445-55.
50. Van der Woude D, Syversen SW, van der Voort EI et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1110-6.
51. Harre U, Georgess D, Bang H et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-802.
52. Kleyer A, Finzel S, Rech J et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014; 73: 854-60.
53. Kuhn KA, Kulik L, Tomooka B et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116: 961-73.
54. Laurent L, Clavel C, Lemaire O et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011; 70: 1052-9.
55. Van SK, Tilleman K, De CM, De KF, Elewaut D, Deforce D. Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther 2010; 12: R132.
56. Suwannalai P, van de Stadt LA, Radner H et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012; 64: 1323-8.
57. Suwannalai P, Britsemmer K, Knevel R et al. Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2014; 73: 270-6.
58. Diebolder CA, Beurskens FJ, de Jong RN et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343: 1260-3.
59. Verpoort KN, Cheung K, Ioan-Facsinay A et al. Fine specific-ity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007; 56: 3949-52.
60. Ioan-Facsinay A, el-Bannoudi H, Scherer HU et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 2011; 70: 188-93.
61. van de Stadt LA, van Schouwenburg PA, Bryde S et al. Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatology (Oxford) 2013; 52: 631-5.
62. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Bozic B, Pruijn GJ. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 2013; 65: 69-80.
63. Kinloch A, Tatzer V, Wait R et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1421-9.
64. Tabushi Y, Nakanishi T, Takeuchi T et al. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics-based analysis. Ann Clin Biochem 2008; 45: 413-7.
65. Nielen MM, van SD, Reesink HW et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
66. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
67. Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012; 8: 144-52.
68. Haj HA, Magnusson PK, Joshua V et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2013; doi: 10.1136/annrheumdis-2013-203947. [Epub ahead of print].